Fig. 6From: Tazemetostat decreases β-catenin and CD13 protein expression in HEPG-2 and Hepatitis B virus-transfected HEPG-2 with decreased cell viabilityEpCAM protein expression levels (ng/ml) in the supernatant of HEPG2 cells or HEPG2 transfected with hepatitis B virus (HBV/HEPG2) after 48 h incubation with different concentrations of Taz or 0.05% DMSO; (*): P < 0.05Back to article page